

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Jun 02, 2021

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-kisqali-reports-longest-median-overall-survival-postmenopausal-hrher2-metastatic-breast-cancer-patients-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-kisqali-reports-longest-median-overall-survival-postmenopausal-hrher2-metastatic-breast-cancer-patients-0>